HLA G Antibody (G233) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NB110-55298

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NB110-55298
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

CyTOF-ready, ELISA, Flow Cytometry, Immunohistochemistry-Frozen, Immunoprecipitation

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2A Clone # G233

Format

BSA Free

Concentration

1.0 mg/ml

View all HLA-G Antibodies »

Product Specifications

Immunogen

HLA-A2.1/human beta2-microglobulin double transgenic mice were immunized with murine L cells transfected with both human beta2-microglobulin and HLA G Antibody (G233)

Specificity

This antibody (clone G233) recognizes several isoforms of HLA-G expressed in all populations of extravillous trophoblast (cell columns, interstitial trophoblast, endovascular trophoblast, placental bed giant cells). HLA-G belongs to the nonclassical MHC Class I molecules (MHC Class Ib). The antibody has been found not to cross-react with any other MHC Class I antigens (HLA-A, -B, -C, -E, -F).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Scientific Data Images for HLA G Antibody (G233) - BSA Free

Flow Cytometry: HLA G Antibody (G233) - BSA Free [NB110-55298]

Flow Cytometry: HLA G Antibody (G233) - BSA Free [NB110-55298]

Flow Cytometry: HLA G Antibody (G233) [NB110-55298] - Surface staining of HLA-G in HLA-G transfectants using anti-HLA-G (G233) purified / GAM-APC.

Applications for HLA G Antibody (G233) - BSA Free

Application
Recommended Usage

ELISA

1:2000

Flow Cytometry

1-4 ug/ml

Immunoprecipitation

1:50
Application Notes
This antibody is Cytof ready.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS (pH 7.4)

Format

BSA Free

Preservative

0.9% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: HLA-G

Human leukocyte antigen (HLA)-G is a non-classical major histocompatibility complex (MHC) class I gene belonging to the HLA class I family. The HLA class I family is subdivided into the classical (HLA-Ia) antigens comprised of HLA-A, -B, and -C molecules and the nonclassical (HLA-Ib) group including the HLA-E, -F, and -G molecules. Seven different splice variants of HLA-G have been observed including four membrane isoforms (HLA-G1, HLA-G2, HLA-G3, and HLA-G4) and three soluble isoforms (HLA-G5, HLA-G6 and HLA-G7). Proteolytic processing of HLA-G1 by metalloproteinases (MMPs) such as MMP-2 produces the soluble isoform, shedding HLA-G1. The HLA-G1 and HLA-G5 isoforms share a similar confirmation to the classical MHC class I protein, consisting of three extracellular domains including alpha1, alpha2, and alpha3 associated with Beta-2-microglobulin (B2M). Other HLA-G variants are shorter, missing one or two of the globular domains and are not bound to B2M. HLA-G receptors include KIR2DL4 (CD158d), with the highest affinity for ILT2 (LILRB1, CD85j) and ILT4 (LILRB2, CD85d) (1,2).

Discovered in cytotrophoblasts, HLA-G is involved in fetal maternal immune tolerance and some studies have linked its downregulation with severe preeclampsia (3). HLA-G mediated immune suppression works by impeding cell proliferation, differentiation, cytotoxicity, cytokine secretion and chemotaxis; and activation of regulatory cells and MDSCs or M2 type macrophage. HLA-G is constitutively expressed in immune-privileged sites such as pancreatic islets, mesenchymal stem cells (MSCs) and the cornea. Upregulation of HLA-G occurs in pathological states including cancer, allo-transplantations, viral infections, autoimmune and inflammatory diseases (4). In cancer, HLA-G expression is induced by hypoxia and has been correlated with advanced tumor stage, tumor metastasis, and poor therapeutic response and survival. HLA-G is an attractive tumor associated-antigen (TAA) for immunotherapy and is considered a major immune checkpoint (ICP).

References

1. Loustau, M., Anna, F., Drean, R., Lecomte, M., Langlade-Demoyen, P., & Caumartin, J. (2020). HLA-G Neo-Expression on Tumors. Front Immunol, 11:1685. PMID: 32922387

2. Lin A, Yan WH. (2018) Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges. Front Immunol. 9:2164. PMID: 30319626

3. Djurisic S, Hviid TV. (2014) HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia. Front Immunol. 5:652. PMID: 25566263

4. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. (2001) Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A. 98(21):12150-12155. PMID: 11572934

Long Name

Major Histocompatibility Complex, Class I, G

Alternate Names

HLA G, HLA-6.0, HLAG, MHC Class I Antigen G, MHC-G

Entrez Gene IDs

3135 (Human)

Gene Symbol

HLA-G

Additional HLA-G Products

Product Documents for HLA G Antibody (G233) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for HLA G Antibody (G233) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.